Andrea S. Blevins Primeau, PhD, MBA

Researchers sought to determine whether adding gemtuzumab ozogamicin to FLAG-Ida would improve rates of relapse in patients with newly-diagnosed AML.

Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or gastroesophageal junction cancer, according to researchers.

Most women with breast cancer do not talk with clinicians about sexual dysfunction that occurs during or after cancer treatment, a survey suggests.

A meta-analysis revealed associations between metformin use and endometrial cancer in patients with type 2 diabetes.

Findings on PET/CT conducted 1 week after the start of pembrolizumab may predict outcomes of the treatment in patients with advanced melanoma.

Prophylaxis with tixagevimab and cilgavimab (Evusheld) reduced the risk of breakthrough SARS-CoV-2 infections and the severity of COVID-19 among patients with hematologic cancers in an Italian study.

Adding palbociclib to letrozole did not improve OS in postmenopausal patients with ER+, HER2- advanced breast cancer in the PALOMA-2 trial.

Hypoxia-guided chemoradiotherapy is feasible for patients with HPV-related oropharyngeal cancer, according to researchers.

Fulvestrant alone or in combination with anastrozole did not provide a benefit over anastrozole alone as neoadjuvant therapy for postmenopausal, ER-rich, HER2-negative, stage II-III breast cancer.

Researchers sought to determine whether golidocitinib would have antitumor activity among patients with relapsed/refractory PTCL.